Table 4.
HR (95% CI) Versus Placebo for Cerebrovascular Events and VTEs (Adjudicated Data)
| Bazedoxifene | Raloxifene | ||
|---|---|---|---|
| 20 mg (n = 1886) |
40 mg (n = 1872) |
60 mg (n = 1849) |
|
| Total stroke | 0.9 (0.40, 1.86) | 1.0 (0.49, 2.17) | 0.9 (0.40, 1.88) |
| Hemorrhagic stroke | 0.5 (0.05, 5.53) | 0.5 (0.05, 5.70) | 0.5 (0.05, 5.65) |
| Ischemic stroke | 0.9 (0.37, 2.22) | 1.2 (0.54, 2.87) | 1.0 (0.42, 2.44) |
| Stroke (unspecified) | 1.0 (0.14, 7.10) | 0.5 (0.05, 5.74) | 0.5 (0.05, 5.54) |
| TIA | 1.3 (0.34, 4.68) | 1.8 (0.53, 6.18) | 0.8 (0.17, 3.41) |
| Any VTE | 1.6 (0.68, 3.94) | 1.7 (0.70, 4.07) | 1.1 (0.44, 2.96) |
| DVT | 8.0 (1.01, 64.25) | 9.4 (1.18, 73.82) | 7.1 (0.88, 57.95) |
| PE | 0.8 (0.17, 3.36) | 0.8 (0.17, 3.47) | 1.0 (0.25, 4.08) |
| RVT | 0.7 (0.11, 4.00) | 0.4 (0.04, 3.32) | 0 |
| Superficial thrombophlebitis | 1.4 (0.55, 3.43) | 2.3 (1.01, 5.33) | 1.7 (0.68, 3.99) |
HR, hazard ratio; CI, confidence interval; VTE, venous thromboembolic event; TIA, transient ischemic attack; DVT, deep vein thrombosis; PE, pulmonary embolus; RVT, retinal vein thrombosis.